Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aurinia Pharmaceuticals Inc
AUPH | US
15.82
USD-0.14
-0.88%
AUPH | US
About Aurinia Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/04/2026
Close
15.82
Open
15.91
High
15.91
Low
15.63
Aurinia Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria Canada.
View LessAUPH | US
Risk
35.7
Sharpe
2.24
Luna's Score
64/100
Recommendation
Hold
Luna says (AUPH | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
17.6%1 month
35.7%3 months
33.7%6 months
37.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
15.15
Price to book
2.82
Debt to equity
0.24
Debt to assets
0.16
Ent. to EBITDA
-7.69
Ent. to rev.
3.78
PEG
-
Other Fundamentals
EBITDA
-27.15M
MarketCap
2.26B
MarketCap(USD)
2.26B
Div. yield
-
Op. margin
-0.77
Erngs. growth
-
Rev. growth
37.80
Ret. on equity
-13.30
Short ratio
5.52
Short perc.
5.09
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.98
Range1M
2.73
Range3M
3.02
Volumes: Market Activity
Rel. volume
0.72
Price X volume
12.75M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -7.69 | - | Cheaper |
| Ent. to Revenue | 3.78 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.82 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 33.74 | - | Lower Risk |
| Debt to Equity | 0.24 | -1.23 | Expensive |
| Debt to Assets | 0.16 | 0.25 | Cheaper |
| Market Cap | 2.26B | - | Emerging |
